Clinical and technical validation studies for diagnostic companies

• Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture.
• Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.
• Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.
• Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA.
• Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

read more


Viroclinics Biosciences receives approval for French Research Tax Credit

Rotterdam, November 3rd

The French ministry of research and innovation approves Viroclinics Biosciences as an intermediate vendor, according to Art. 244 quarter B of the French Fiscal Code. The French Tax Credit Incentive (Crédit d’Impôt Recherche or CIR) is a tax relief measure for companies focused on Research & Development activities. It is a volume based R&D tax for organizations based in France.








The incentive is also applicable to Research & Development studies or projects outsourced to approved third parties, such as Viroclinics Biosciences. The scope of expenditures1 that are eligible for tax deduction is based on:
– Depreciation of newly acquired fixed assets;
– Personnel expenditure for researchers;
– Research expenditure sub-contracted to public research bodies and private research organizations approved by the concerning ministry;
– and more depending on the specifications of the R&D project.

With the CIR recognition the tax credit rate for R&D is 30% of outlays up to € 100 million per year, and 5% over this limit. The CIR is deducted from taxes of the concerning organization. As a specialized Contract Research Organization, Viroclinics Biosciences is the ideal partner for projects and studies (sub) contracted by French-based companies. For further information, please feel free to contact your usual representative or alternatively send a request for information here.


Additional Information:

– Viroclinics Biosciences’ approval certificate by the French government can be downloaded here.
– A summary of the eligible expenditures is published here.
– The full background of Article 244/ quarter B can be found here.
– To benefit from the CIR program a declaration 2069A has to be submitted. The concerning forms can be downloaded here.

[1Source: Official French Governmental Website for Legal Information, 2017, ]

Please note that Viroclinics Biosciences B.V. is not liable for the actual assignment of tax credits. The allocation of CIR related incentives falls under the jurisdiction of the French government.



 latest Posters

Data Loggers for Measuring Activity Levels Provide a Powerful Tool for Clinical Scoring in Experimental Ferrets


Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Ferrets: a novel model for antiviral testing


Influenza virus and RSV ViroSpot™ Assays for high-throughput virology testing